
Altimmune, Inc. (NASDAQ:ALT – Free Report) – Investment analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Altimmune in a research note issued on Tuesday, November 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.62) for the year, down from their previous estimate of ($0.56). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Altimmune’s Q4 2026 earnings at ($0.17) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.73) EPS, FY2028 earnings at ($0.67) EPS, FY2029 earnings at ($0.35) EPS and FY2030 earnings at ($0.09) EPS.
A number of other analysts have also commented on ALT. Wall Street Zen lowered Altimmune from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 14th. Weiss Ratings downgraded shares of Altimmune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, November 13th. B. Riley Financial restated a “buy” rating on shares of Altimmune in a report on Friday, November 13th. Evercore restated an “outperform” rating on shares of Altimmune in a report on Wednesday, September 23rd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Friday, November 13th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Altimmune currently has a consensus rating of “Moderate Buy” and an average price target of $14.33.
Read Our Latest Report on Altimmune
Altimmune Price Performance
Shares of Altimmune stock opened at $1.39 on Thursday. The company has a quick ratio of 23.93, a current ratio of 23.93 and a debt-to-equity ratio of 0.08. The company has a market cap of $270.48 million, a PE ratio of -1.93 and a beta of 0.16. The business has a 50 day moving average of $2.47 and a 200 day moving average of $3.09. Altimmune has a 52 week low of $1.38 and a 52 week high of $6.44.
Altimmune (NASDAQ:ALT – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in shares of Altimmune by 12.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 2,479,456 shares of the company’s stock valued at $7,091,000 after purchasing an additional 265,006 shares during the period. Nantahala Capital Management LLC boosted its position in shares of Altimmune by 14.7% during the third quarter. Nantahala Capital Management LLC now owns 1,720,000 shares of the company’s stock valued at $4,919,000 after purchasing an additional 220,000 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Altimmune by 268.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock worth $3,221,000 after purchasing an additional 762,223 shares during the period. Bank of New York Mellon Corp purchased a new stake in Altimmune in the second quarter worth $2,097,000. Finally, Bank of America Corp DE grew its stake in Altimmune by 48.6% in the first quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock worth $1,756,000 after purchasing an additional 186,420 shares during the period. Institutional investors own 78.05% of the company’s stock.
Insiders Place Their Bets
In other news, CEO Jerome Durso acquired 30,700 shares of the business’s stock in a transaction on Friday, November 13th. The shares were acquired at an average cost of $1.62 per share, with a total value of $49,734.00. Following the transaction, the chief executive officer owned 93,200 shares in the company, valued at $150,984. The trade was a 49.12% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders purchased 50,700 shares of company stock worth $82,334. Insiders own 1.60% of the company’s stock.
Top Altimmune Stories
These are some of the ALT stories that stood out recently:
- Positive Sentiment: HC Wainwright raised its loss-per-share estimates for FY2029 from $0.39 to $0.35 and FY2030 from $0.15 to $0.09, signaling a somewhat improved longer-term outlook.
- Neutral Sentiment: HC Wainwright kept its Buy rating on ALT, though its revised forecasts still project losses in the periods discussed.
- Negative Sentiment: The analyst cut estimates for Q4 2026 through 2027 and FY2026–FY2028. Notably, FY2027’s projected loss widened from $0.63 to $0.73 per share, while FY2026’s increased from $0.56 to $0.62. The broad set of estimate reductions could weigh on sentiment and help explain the stock’s weakness.
Altimmune Company Profile
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
Further Reading
- Five stocks we like better than Altimmune
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
